Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5363229 | 0.95 | OPRK1 (0.45) | OPRK1ALDH1A1OPRL1OPRM1OPRD1 | |
| SCHEMBL6086382 | 0.84 | ALDH1A1 (0.54) | OPRK1ALDH1A1OPRL1OPRM1OPRD1 | |
| SCHEMBL6086308 | 0.81 | CRBN (0.41) | OPRK1OPRM1OPRD1HTR2C | |
| SCHEMBL1671403 | 0.80 | DPP4 (0.47) | ALDH1A1 | |
| SCHEMBL6086918 | 0.79 | PTPN11 (0.43) | ALDH1A1 | |
| SCHEMBL5310259 | 0.79 | CYP1A2 (0.41) | ALDH1A1 | |
| SCHEMBL6088673 | 0.78 | PTPN11 (0.40) | ALDH1A1 | |
| SCHEMBL6087739 | 0.74 | PLD1 (0.51) | OPRK1OPRL1OPRM1OPRD1SLC6A9 | |
| SCHEMBL6086561 | 0.73 | TSHR (0.40) | OPRK1ALDH1A1OPRM1OPRD1HTR1A | |
| SCHEMBL6088414 | 0.72 | CYP3A4 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115601-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050261322-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261322-A1 | HIV integrase inhibitors | TYMP, PAICS, TYMS | OPRK1 2289/4885ALDH1A1 539/4885OPRL1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.